(EXEL) Exelixis - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 11.808m USD | Total Return: 18.5% in 12m

Stock Cancer Drugs, Targeted Therapies, Clinical Trials
Total Rating 54
Safety 89
Buy Signal 0.21
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 11,808m
Avg Trading Vol: 97.4M USD
ATR: 2.82%
Peers RS (IBD): 23.8
Risk 5d forecast
Volatility38.7%
Rel. Tail Risk-24.5%
Reward TTM
Sharpe Ratio0.46
Alpha4.28
Character TTM
Beta0.590
Beta Downside-0.700
Drawdowns 3y
Max DD25.34%
CAGR/Max DD1.19
EPS (Earnings per Share) EPS (Earnings per Share) of EXEL over the last years for every Quarter: "2021-03": 0.005, "2021-06": 0.3, "2021-09": 0.12, "2021-12": 0.29, "2022-03": 0.21, "2022-06": 0.22, "2022-09": 0.23, "2022-12": -0.09, "2023-03": 0.12, "2023-06": 0.25, "2023-09": 0.1, "2023-12": 0.27, "2024-03": 0.2, "2024-06": 0.77, "2024-09": 0.4, "2024-12": 0.55, "2025-03": 0.62, "2025-06": 0.75, "2025-09": 0.78, "2025-12": 0.97, "2026-03": 0,
EPS CAGR: -24.69%
EPS Trend: 59.5%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of EXEL over the last years for every Quarter: 2021-03: 270.23, 2021-06: 385.177, 2021-09: 328.423, 2021-12: 451.14, 2022-03: 355.98, 2022-06: 419.427, 2022-09: 411.738, 2022-12: 423.917, 2023-03: 408.788, 2023-06: 469.848, 2023-09: 471.92, 2023-12: 479.652, 2024-03: 425.226, 2024-06: 637.178, 2024-09: 539.542, 2024-12: 566.755, 2025-03: 555.447, 2025-06: 568.261, 2025-09: 597.755, 2025-12: 598.663, 2026-03: null,
Rev. CAGR: 14.87%
Rev. Trend: 89.5%
Last SUE: -0.01
Qual. Beats: 0
Description: EXEL Exelixis

Exelixis, Inc. is an oncology company specializing in the discovery, development, and commercialization of cancer treatments in the United States.

The company markets CABOMETYX for advanced renal cell carcinoma and COMETRIQ for medullary thyroid cancer, both derived from cabozantinib. It also offers COTELLIC for advanced melanoma and MINNEBRO for hypertension in Japan.

Exelixis has a pipeline of drug candidates including zanzalintinib, XL309, XB010, XB628, and XB371. The biotechnology sector is characterized by high research and development costs and a long drug approval process.

The company engages in numerous research collaborations and licensing agreements with other pharmaceutical firms. The pharmaceutical industry often relies on such partnerships to share development risks and expand market reach.

For more detailed financial metrics and comparative analysis, consider exploring ValueRay.

Headlines to Watch Out For
  • CABOMETYX sales drive oncology revenue growth
  • Pipeline drug development faces clinical trial risks
  • Regulatory approvals crucial for new cancer therapies
  • Competition from novel cancer treatments impacts market share
Piotroski VR‑10 (Strict) 5.5
Net Income: 782.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.30 > 0.02 and ΔFCF/TA 8.70 > 1.0
NWC/Revenue: 44.72% < 20% (prev 49.05%; Δ -4.33% < -1%)
CFO/TA 0.31 > 3% & CFO 884.3m > Net Income 782.6m
Net Debt (-309.4m) to EBITDA (934.7m): -0.33 < 3
Current Ratio: 3.56 > 1.5 & < 3
Outstanding Shares: last quarter (281.9m) vs 12m ago 0.05% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 80.11% > 50% (prev 73.57%; Δ 6.54% > 0%)
Interest Coverage Ratio: -25.43 > 6 (EBITDA TTM 934.7m / Interest Expense TTM -35.6m)
Altman Z'' 4.29
A: 0.36 (Total Current Assets 1.44b - Total Current Liabilities 405.6m) / Total Assets 2.84b
B: -0.03 (Retained Earnings -76.8m / Total Assets 2.84b)
C: 0.31 (EBIT TTM 905.6m / Avg Total Assets 2.90b)
D: -0.11 (Book Value of Equity -73.1m / Total Liabilities 683.1m)
Altman-Z'' Score: 4.29 = AA
Beneish M -2.97
DSRI: 1.01 (Receivables 286.9m/265.4m, Revenue 2.32b/2.17b)
GMI: 1.00 (GM 96.39% / 96.49%)
AQI: 1.06 (AQ_t 0.40 / AQ_t-1 0.38)
SGI: 1.07 (Revenue 2.32b / 2.17b)
TATA: -0.04 (NI 782.6m - CFO 884.3m) / TA 2.84b)
Beneish M-Score: -2.97 (Cap -4..+1) = A
What is the price of EXEL shares? As of April 03, 2026, the stock is trading at USD 42.89 with a total of 1,883,229 shares traded.
Over the past week, the price has changed by +3.59%, over one month by +6.95%, over three months by +0.69% and over the past year by +18.47%.
Is EXEL a buy, sell or hold? Exelixis has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy EXEL.
  • StrongBuy: 7
  • Buy: 4
  • Hold: 9
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the EXEL price?
Wallstreet Target Price 46.8 9.2%
Analysts Target Price 46.8 9.2%
EXEL Fundamental Data Overview as of 02 April 2026
P/E Trailing = 15.8417
P/E Forward = 13.7741
P/S = 5.0892
P/B = 5.1538
P/EG = 2.2685
Revenue TTM = 2.32b USD
EBIT TTM = 905.6m USD
EBITDA TTM = 934.7m USD
Long Term Debt = 173.0m USD (from capitalLeaseObligations, last quarter)
 Short Term Debt = unknown (none)
 Debt = 173.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -309.4m USD (from netDebt column, last quarter)
Enterprise Value = 10.92b USD (11.81b + Debt 173.0m - CCE 1.06b)
Interest Coverage Ratio = -25.43 (Ebit TTM 905.6m / Interest Expense TTM -35.6m)
EV/FCF = 12.71x (Enterprise Value 10.92b / FCF TTM 859.2m)
FCF Yield = 7.87% (FCF TTM 859.2m / Enterprise Value 10.92b)
FCF Margin = 37.03% (FCF TTM 859.2m / Revenue TTM 2.32b)
Net Margin = 33.73% (Net Income TTM 782.6m / Revenue TTM 2.32b)
 Gross Margin = unknown ((Revenue TTM 2.32b - Cost of Revenue TTM 83.7m) / Revenue TTM)
 Tobins Q-Ratio = 3.84 (Enterprise Value 10.92b / Total Assets 2.84b)
Interest Expense / Debt = 15.20% (Interest Expense 26.3m / Debt 173.0m)
Taxrate = 3.23% (8.16m / 252.7m)
NOPAT = 876.4m (EBIT 905.6m * (1 - 3.23%))
Current Ratio = 3.56 (Total Current Assets 1.44b / Total Current Liabilities 405.6m)
Debt / Equity = 0.08 (Debt 173.0m / totalStockholderEquity, last quarter 2.16b)
Debt / EBITDA = -0.33 (Net Debt -309.4m / EBITDA 934.7m)
Debt / FCF = -0.36 (Net Debt -309.4m / FCF TTM 859.2m)
Total Stockholder Equity = 2.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 27.02% (Net Income 782.6m / Total Assets 2.84b)
RoE = 36.89% (Net Income TTM 782.6m / Total Stockholder Equity 2.12b)
RoCE = 39.47% (EBIT 905.6m / Capital Employed (Equity 2.12b + L.T.Debt 173.0m))
RoIC = 41.31% (NOPAT 876.4m / Invested Capital 2.12b)
WACC = 8.16% (E(11.81b)/V(11.98b) * Re(8.06%) + D(173.0m)/V(11.98b) * Rd(15.20%) * (1-Tc(0.03)))
Discount Rate = 8.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -5.11%
[DCF] Terminal Value 81.08% ; FCFF base≈769.0m ; Y1≈948.7m ; Y5≈1.62b
[DCF] Fair Price = 104.9 (EV 26.95b - Net Debt -309.4m = Equity 27.26b / Shares 259.7m; r=8.16% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 59.50 | EPS CAGR: -24.69% | SUE: -4.0 | # QB: 0
Revenue Correlation: 89.48 | Revenue CAGR: 14.87% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.81 | Chg7d=-0.001 | Chg30d=-0.020 | Revisions Net=+1 | Analysts=11
EPS current Year (2026-12-31): EPS=3.40 | Chg7d=+0.003 | Chg30d=-0.038 | Revisions Net=+2 | Growth EPS=+10.2% | Growth Revenue=+11.4%
EPS next Year (2027-12-31): EPS=3.93 | Chg7d=-0.066 | Chg30d=-0.289 | Revisions Net=-2 | Growth EPS=+15.7% | Growth Revenue=+15.1%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.7% (Discount Rate 8.1% - Earnings Yield 6.3%)
[Growth] Growth Spread = +9.2% (Analyst 11.0% - Implied 1.7%)
External Resources
Dataroma Stockcircle